5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny
Cefadroxil
CAS: 50370-12-2
Molecular Formula: C16H17N3O5S
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Names and Identifiers
| Name | Cefadroxil |
| Synonyms | cdx bl-s578 CEFAMOX bidocef Cefadroxil P-HYDROXYCEPHALEXINE Cefadroxil Anhydrous (6r-(6-alpha,7-beta(r*)))-l)acetyl)amino)-3-methyl-8-oxo 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny (6R,7R)-7-[(R)-2-AMINO-2-(4-HYDROXY-PHENYL)-ACETYLAMINO]-3-METHYL-8-OXO-5-THIA-1-AZA-BICYCLO[4.2.0]OCT-2-ENE-2-CARBOXYLIC ACID (6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| CAS | 50370-12-2 |
| EINECS | 256-555-6 |
| InChI | InChI=1/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1 |
| InChIKey | BOEGTKLJZSQCCD-UEKVPHQBSA-N |
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Physico-chemical Properties
| Molecular Formula | C16H17N3O5S |
| Molar Mass | 363.39 |
| Density | 1.59 |
| Melting Point | 197°C (rough estimate) |
| Boling Point | 238°C (rough estimate) |
| Flash Point | 431.5°C |
| Vapor Presure | 2.71E-26mmHg at 25°C |
| Appearance | powder or crystals |
| pKa | 3.12±0.50(Predicted) |
| Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
| Refractive Index | 1.6390 (estimate) |
| Physical and Chemical Properties | 66592-87-8 (monohydrate) |
| Use | For Staphylococcus, Streptococcus, Pneumonia coccus, Escherichia coli and other urinary system, respiratory tract, skin, facial features and gastrointestinal tract infection treatment |
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Risk and Safety
| Hazard Symbols | Xn - Harmful |
| Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. R42/43 - May cause sensitization by inhalation and skin contact. |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
| WGK Germany | 2 |
| RTECS | XI0337000 |
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Standard
Authoritative Data Verified Data
(6R,7R)-3-methyl -7-[(R)-2-amino -2-(4-hydroxyphenyl) acetamido]-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid monohydrate. The content of cefadroxil (calculated as C16H17N3O5S) shall not be less than 95.0% calculated as anhydrous.
Last Update：2024-01-02 23:10:35
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Trait
Authoritative Data Verified Data
- This product is white or off-white crystalline powder with specific odor.
- This product is slightly soluble in water, and almost insoluble in ethyl ether or ethyl ether.
specific rotation
take this product, precision weighing, water dissolution and quantitative dilution of about 6mg per lml solution, according to the law (General 0621), specific rotation of 165 ° to 178 °.
Last Update：2022-01-01 11:41:33
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Differential diagnosis
Authoritative Data Verified Data
- take an appropriate amount of this product, add an appropriate amount of water, ultrasonic to dissolve and dilute to make a solution containing about 12.5mg per 1ml, take 1ml of the solution, add 3 drops of ferric chloride test solution, that is, Brown yellow.
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 596).
Last Update：2022-01-01 11:41:34
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Exam
Authoritative Data Verified Data
crystallinity
take this product, according to the law inspection (General 0981), should comply with the provisions.
acidity
take this product, add water to make a solution containing 5mg per lml, according to the law (General 0631) ,pH value should be 4.0~6.0.
Related substances
take an appropriate amount of this product, accurately weigh, add mobile phase A to dissolve and quantitatively dilute to prepare A solution containing about 1 mg per 1ml, as A test solution; Take 1ml for precision measurement, set in A 100ml measuring flask, dilute to the scale with mobile phase A, and shake to serve as A control solution. Accurately weigh about 10mg of a-p-hydroxyphenylglycine reference product, put it in A 10ml measuring flask, add appropriate amount of mobile phase a, ultrasonic dissolve and dilute to the scale, shake well, and use as reference solution (1); precisely weigh about 10mg of 7-aminodeacetoxycephalosporanic acid reference substance, put it in a 10ml measuring flask, and add phosphate buffer solution with pH 7.0 (take 28.4g of disodium hydrogen phosphate anhydrous, and add of water to dissolve the solution, adjust the pH to 30% with 7.0 phosphoric acid solution, dilute to ML with water, stick well) appropriate amount, ultrasonic dissolution and dilution to the scale, shake, as a control solution (2). 1ml of each of the control solution (1) and (2) was accurately measured, and the solution was placed in A 100ml measuring flask, diluted to the scale with mobile phase A, and shaken to obtain an impurity control solution. According to the determination by high performance liquid chromatography (General rule 0512), silica gel bonded with eighteen alkyl silane is used as the filler; Mobile phase A is 0.02mol/L potassium dihydrogen phosphate solution (2.72g of potassium dihydrogen phosphate, of water is added to dissolve, adjust the pH value to 5.0 with 1 mol/L potassium hydroxide solution, dilute to ML with water, mix well); Mobile phase B is fermentation; The detection wavelength is 220nm; Perform linear gradient elution according to the following table, 20ul of the mixed solution of the impurity reference solution and the test solution (9:1) is injected into the liquid chromatograph, and the chromatogram is recorded. The retention time of the cefadroxil peak is about 10 minutes, and the degree of separation between the-p-hydroxyphenylglycine peak and the aminodesacetoxycephalosporin acid peak should be greater than 5.0, the degree of separation between the peak of 7-aminodeacetoxycephalosporanic acid and the peak of cefadroxil should be greater than 5.0. The sample solution, the control solution and the impurity reference solution were accurately sampled at 20 u1, respectively injected into the human liquid chromatograph, and the chromatogram was recorded. If there are impurity peaks in the chromatogram of the test solution, P-hydroxyphenylglycine and 7-aminodesacetoxycephalosporinic acid shall not exceed 1.0% based on the peak area calculated by the external standard method; the Peak area of other individual impurities shall not be greater than the main peak area of the control solution (1.0% ) , and the sum of the peak areas of other impurities shall not be greater than 3 times (3.0%) of the main peak area of the control solution. The peaks in the chromatogram of the test solution which were 0.05 times smaller than the main peak area of the control solution were ignored.
moisture
take this product, according to the moisture determination method (General 0832 first method 1), the moisture content should be 4.2% ~ 6.0%.
Last Update：2022-01-01 11:41:35
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Content determination
Authoritative Data Verified Data
measured by high performance liquid chromatography (General 0512).
chromatographic conditions and system suitability test
silica gel bonded with eighteen alkyl silane was used as the filler, and the mobile phase A- mobile phase B(98:2) under the item of related substances was used as the mobile phase. The detection wavelength was 230nm; take appropriate amount of cefadroxil reference and 7-aminodeacetoxycephalosporin acid reference, add appropriate amount of phosphate buffer pH 7.0 under the item of related substances, sonicate and dissolve, then diluted with 0.02mol/L potassium dihydrogen phosphate solution to make about 0.3mg and 0.lmg mixed solution, take lOul injection liquid chromatography, record chromatogram, cefadroxil peak and 7-amino deacetoxycephalosporin acid peak separation degree should be greater than 5.0.
assay
take an appropriate amount of this product, precision weighing, add 0.02mol/L potassium dihydrogen phosphate solution to dissolve and quantitatively dilute to make a solution containing about 0.3mg per lml, as a test solution, 10 u1 was injected into the liquid chromatograph, and the chromatogram was recorded. An appropriate amount of cefadroxil reference was taken and determined by the same method. According to the external standard method to calculate the peak area, that is.
Last Update：2022-01-01 11:41:35
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Category
Authoritative Data Verified Data
B-lactam antibiotics, cephalosporins.
Last Update：2022-01-01 11:41:36
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Storage
Authoritative Data Verified Data
shade, seal, and store in a cool place.
Last Update：2022-01-01 11:41:36
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Cefadroxil tablets
Authoritative Data Verified Data
This product contains cefadroxil (according to C16H17N3O5S) should be 90.0% to 110.0% of the label amount.
trait
This product is white or off-white.
identification
- Take appropriate amount of fine powder of this product, add appropriate amount of water, ultrasonic to dissolve and dilute to prepare a solution containing about 12.5mg of cefadroxil (as measured by C16HI7N305S) per 1ml, filter, and take 1ml of filtrate, add 3 drops of ferric chloride solution, which shows Brown yellow.
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
examination
- relevant substances: Take appropriate amount of fine powder of this product, add mobile phase A to dissolve and dilute to prepare A solution containing about 1 mg of cefadroxil (as measured by C16H17N3O5S) per 1 ml, and filter it through, take the continued filtrate as the test solution, according to the method under the item of cefadroxil determination, should comply with the provisions.
- the dissolution of this product, according to the dissolution and release determination method (General rule 0931 second method), water 900ml as the dissolution medium, the speed of 50 rpm, according to the law, after 30 minutes, take an appropriate amount of the solution, filter, take a precise amount of the filtrate, and add water to dilute it quantitatively to make a solution containing about 25ug of cefadroxil (according to C16H17N3O5S) per lml, according to UV-visible spectrophotometry (General rule 0401), the absorbance was measured at the wavelength of 263nm, water was added to dissolve and quantitatively diluted to prepare a solution containing about 25% per 1 ml, which was measured by the same method, and the dissolution amount of each tablet was calculated. The limit is 75% of the labeled amount and shall be in accordance with the provisions.
- others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).
Content determination
Take 10 tablets of this product, precision weighing, fine grinding, precision weighing appropriate amount (about equivalent to cefadroxil, 0.15g according to C16H17N3O5S), and put it in a 100ml measuring flask, add 0.02mol/L potassium dihydrogen phosphate solution under cefadroxil to dissolve and dilute to scale, shake well, filter, take appropriate amount of filtrate, quantitatively dilute with the above 0.02mol/L potassium dihydrogen phosphate solution to prepare a solution containing about mg of cefadroxil (calculated as C16H17N3O5S) per 1 ml as a test solution, according to the method under the terms of cefadroxil, obtained.
category
Same as cefadroxil.
specification
Based on C16H17N3O5S (1)0.125g (2)0.25g(3)0.5g
storage
sealed and stored in a cool place.
Last Update：2022-01-01 11:41:37
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Cefadroxil capsules
Authoritative Data Verified Data
This product contains cefadroxil (according to C16H17N305S) should be 90.0% ~ 110.0% of the label amount.
trait
The contents of this product are white or off-white powder or granules.
identification
- take an appropriate amount of the contents of this product, add an appropriate amount of water, ultrasonic to dissolve and dilute to prepare a solution containing about 12.5mg of cefadroxil (according to C16H17N305S) per 1ml, filter, 1ml of the continued filtrate was taken, and 3 drops of ferric chloride test solution were added, which was brownish yellow.
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
examination
- relevant substances: Take appropriate amount of the contents of this product, add mobile phase A to dissolve and dilute to make A solution containing about 1 mg of cefadroxil (as measured by C16H17N305S) per 1 ml, filter, take the continued filtrate as the test solution, according to the method under the item of cefadroxil determination, should comply with the provisions.
- moisture the contents of this product shall not contain more than 0832 of moisture as determined by the method for moisture determination (General rule 8.0%, Method 1).
- the dissolution of this product, according to the dissolution and release determination method (General rule 0931 first method), with water as the dissolution medium, the speed is 100 rpm, according to the law, after 30 minutes, take the appropriate amount of the solution, filter, take the appropriate amount of the filtrate, and dilute it quantitatively with water to make a solution containing about 25 of cefadroxil (as measured by C16H17N305S) per 1 ml, according to UV-visible spectrophotometry (General rule 0401), the absorbance was measured at the wavelength of 263nm, the solution containing about 25ug per 1 ml was prepared by dissolving and quantitatively diluting with water, and the dissolution amount of each particle was calculated by the same method. The limit is 80% of the labeled amount and shall be in accordance with the provisions.
- others should comply with the relevant provisions under the capsule (General 0103).
Content determination
take the contents under the difference of loading amount, mix them evenly, weigh appropriately (approximately equivalent to cefadroxil, 0.158 based on C16H17N305S), and place them in a 100ml measuring flask, add 0.02mol/L potassium dihydrogen phosphate solution of cefadroxil to dissolve and dilute to the scale, shake well, filter, take proper amount of filtrate, quantitatively dilute with the above 0.02mol/L potassium dihydrogen phosphate solution to prepare a solution containing about mg of cefadroxil (calculated as C16H17N305S) per 1 ml as a test solution, according to the method under the terms of cefadroxil, obtained.
category
Same as cefadroxil.
specification
Based on C16H17N305S (l)0.125g (2)0.25g(3)0.5g
storage
light shielding, sealed, stored in the cool dark.
Last Update：2022-01-01 11:41:38
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny - Cefadroxil granules
Authoritative Data Verified Data
This product contains cefadroxil (according to C16H17N305S) should be 90.0% ~ 110.0% of the label amount.
trait
This product is soluble granules; Sweet taste.
identification
- take 1 bag of this product, add an appropriate amount of dilute ethanol and shake for 2-3 minutes, and make a solution containing about 25mg of cefadroxil (based on C16H17N305S) per 1ml of dilute ethanol, after allowing to stand still, take 1ml of supernatant, add 0.5 of basic copper tartrate solution, and shake well to show dark green color.
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
examination
- acidity: take this product and add water to make a solution containing about 50mg of cefadroxil (according to C16H17N3O5S) per 1 ml, and determine it according to law (General rule 0631). The pH value should be 4.5~6.0.
- appropriate amount of fine powder under the content determination item of related substances is taken, dissolved and diluted with mobile phase A to prepare A solution containing about 1 mg of cefadroxil (calculated as C16H17N305S) per 1 ml, filtered, the filtrate was taken as the test solution, which was determined according to the method under the item of cefadroxil, and the contents of 7-aminodeacetoxycephalosporanic acid and a-p-hydroxyphenylglycine were calculated by the peak area according to the external standard method, 1.0% of the labeled amount shall not be exceeded; The peak area of other individual impurities shall not be greater than the main peak area of the control solution (1.0%).
- weight loss on drying this product shall be dried at 105°C to constant weight, and the weight loss shall not exceed 2.0% (General rule 0831).
- others should comply with the relevant provisions under The granule (General Principle 0104).
Content determination
take the contents under the difference of loading amount, grind them finely, weigh appropriately (about 0.15g equivalent to cefadroxil, based on C16H17N305S), and place them in lOOml measuring flask, add 0.02mol/L potassium dihydrogen phosphate solution under the related substances of cefadroxil to dissolve and dilute to the scale, shake well, filter, accurately take appropriate amount of filtrate, add the above 0.02mol/L potassium dihydrogen phosphate solution to make a solution containing about mg of cefadroxil (calculated as C16H17N305S) per 1 ml, as a test solution, according to the method under the terms of cefadroxil, obtained.
category
Same as cefadroxil.
specification
Based on C16H17N305S (1)0.125g (2)0.25g
storage
sealed and stored in a cool place.
Last Update：2022-01-01 11:41:39
Supplier List
Multiple SpecificationsSpot supply
Product Name: BL-S 578 Visit Supplier Webpage Request for quotationCAS: 50370-12-2
Tel: 609-228-6898
Email: sales@medchemexpress.com
tech@medchemexpress.com
Mobile: 609-228-6898
Spot supply
Product Name: Cefadroxil Visit Supplier Webpage Request for quotationCAS: 50370-12-2
Tel: +86-400-900-4166
Email: product@acmec-e.com
Mobile: +86-18621343501
QQ: 2881950922
Wechat: 18621343501
WhatsApp: +86-18621343501
Spot supply
Product Name: Cefadroxil Visit Supplier Webpage Request for quotationCAS: 50370-12-2
Tel: +86-18821248368
Email: Int06@meryer.com
Mobile: +86-18821248368
QQ: 495145328
WhatsApp: +86-18821248368
Multiple SpecificationsSpot supply
Product Name: BL-S 578 Visit Supplier Webpage Request for quotationCAS: 50370-12-2
Tel: 609-228-6898
Email: sales@medchemexpress.com
tech@medchemexpress.com
Mobile: 609-228-6898
Spot supply
Product Name: Cefadroxil Visit Supplier Webpage Request for quotationCAS: 50370-12-2
Tel: +86-400-900-4166
Email: product@acmec-e.com
Mobile: +86-18621343501
QQ: 2881950922
Wechat: 18621343501
WhatsApp: +86-18621343501
Spot supply
Product Name: Cefadroxil Visit Supplier Webpage Request for quotationCAS: 50370-12-2
Tel: +86-18821248368
Email: Int06@meryer.com
Mobile: +86-18821248368
QQ: 495145328
WhatsApp: +86-18821248368
View History
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylicacid,7-((amino(4-hydroxypheny
181517-99-7
2-[2-(dimethylamino)ethoxy]-ethano
2-溴-6-氰基吡嗪
12036-02-1
Cyclopropanecarbonyl chloride, 3-ethenyl-2,2-dimethyl- (9CI)
烟酰胺核糖氯化物
4-(5-OXO-4,5-DIHYDRO-PYRAZOL-1-YL)-BENZENESULFONAMIDE
洛美沙星羧酸物
3,3-蒽-9,10-双丙烯酸
181517-99-7
2-[2-(dimethylamino)ethoxy]-ethano
2-溴-6-氰基吡嗪
12036-02-1
Cyclopropanecarbonyl chloride, 3-ethenyl-2,2-dimethyl- (9CI)
烟酰胺核糖氯化物
4-(5-OXO-4,5-DIHYDRO-PYRAZOL-1-YL)-BENZENESULFONAMIDE
洛美沙星羧酸物
3,3-蒽-9,10-双丙烯酸